Our grantees represent some of the finest minds in the male contraception research community from around the world.
We make our grants through a variety of funding mechanisms, always prioritizing our mission and vision of driving male contraception closer to clinical trials. We value diversity in our portfolio, and our focus on non-hormonal and reversible methods of contraception ensures that these options can meet the needs of more users.
Male contraception is a field with long-term goals and near-term gains that can be made today. All towards ensuring a mix of contraceptive options for men and their partners.
One such near-term gain is with YourChoice Therapeutics, developing a reversible male contraceptive drug, YCT-529, which prevents the production of new sperm. MCI has both a grant and a program-related investment with YourChoice, which will help facilitate the necessary work that progresses YCT-529 towards first-in-human studies and eventual FDA approval.
Nadja Mannowetz, Co-Founder & CSO of YourChoice Therapeutics
MCI Grantee & Fellow Conversations:
Natalia Rivera Sanchez
To ensure a productive future for contraceptive development, Male Contraceptive Initiative also provides funding for young researchers interested in male contraception.
Our Fellowship program provides direct research support, and our Trainee Success program supports travel, workshops, and other professional development opportunities for trainees.
In this section we share a collection of our current funding recipients, along with the lofty hypothetical realities that they are diligently working towards through their research and development efforts. Please click on any of the images to be directed to each awardee's profile page in order to learn more about their work that MCI is supporting.
Completed Grants & Fellowships
Male Contraceptive Initiative has provided funding support to the research community investigating new methods of non-hormonal, reversible male contraceptives since 2017. For a list of our previous grant awardees and fellowships, click here.